Apparatus for treatment of cardiac valves and method of its manufacture

Information

  • Patent Grant
  • 9498329
  • Patent Number
    9,498,329
  • Date Filed
    Monday, October 21, 2013
    10 years ago
  • Date Issued
    Tuesday, November 22, 2016
    7 years ago
Abstract
A prosthetic valve including a replacement valve having a tubular valve body wall, an expandable stent having a framework with first and second ends, and suturing holding the framework to the valve body at the first and second ends. The suturing at the first end is colored differently from the suturing at the second end.
Description
TECHNICAL FIELD

The invention relates generally to treatment of cardiac valve disease and more particularly to replacement of malfunctioning pulmonary valves.


BACKGROUND

Recently, there has been increasing interest in minimally invasive and percutaneous replacement of cardiac valves. In the context of pulmonary valve replacement, U.S. Patent Application Publication Nos. 2003/0199971 A1 and 2003/0199963 A1, both filed by Tower, et al., describe a valved segment of bovine jugular vein, mounted within an expandable stent, for use as a replacement pulmonary valve. The replacement valve is mounted on a balloon catheter and delivered percutaneously via the vascular system to the location of the failed pulmonary valve and expanded by the balloon to compress the valve leaflets against the right ventricular outflow tract, anchoring and sealing the replacement valve. As described in the articles: Percutaneous Insertion of the Pulmonary Valve, Bonhoeffer, et al., Journal of the American College of Cardiology 2002; 39: 1664-1669 and Transcatheter Replacement of a Bovine Valve in Pulmonary Position, Bonhoeffer, et al., Circulation 2000; 102: 813-816, the replacement pulmonary valve may be implanted to replace native pulmonary valves or prosthetic pulmonary valves located in valved conduits. Surgical procedures for percutaneous pulmonary valve implantation are described in Khambadkone et al., Percutaneous Pulmonary Valve Implantation in Humans, Circulation, Pp. 1189-1197 (Aug. 23, 2005).


Other implantables and implant delivery devices are disclosed in published U.S. Patent Application No. 2003-0036791-A1 and European Patent Application No. 1 057 460-A1.


SUMMARY

The present invention is particularly directed to valves of the type generally described in the Tower et al. and Bonhoeffer, et al. references cited above as used within a prosthetic valve or valve system. However, the invention may also be useful in other types of valves, particularly valves which take the form of a generally tubular valve body of natural or synthetic material, in which valve leaflets are provided. Examples of such other valves include those described in U.S. Pat. Nos. 6,719,789 and 5,480,424, both issued to Cox.


In one aspect of the invention, an improved suturing technique is employed to attach the valved venous segment or other replacement valve to its associated stent. In at least one aspect, in order to prevent inward bowing of the walls of the venous segment or other substantially tubular valve body, the tissue of the segment or other tubular valve body is attached to the stent at all or substantially all of the angled portions of the stent. Alternatively, sutures may be distributed about the stent at other locations such that no portion of the venous wall or other tubular valve body is more than a few millimeters from a suture.


In another aspect of the invention a prosthetic valve is provided that includes a replacement valve having a substantially tubular valve body wall, an expandable stent having a framework including a plurality of “V” structures, each having a base, and sutures located at each base holding the valve body wall to the stent. The sutures are preferably no further than 7 mm from one of the sutures. The replacement valve can be a valved vein segment and the valve body wall can be the vein segment's wall. The valved vein segment can be a valved segment of bovine jugular vein.


In another aspect of the invention, an assembly consisting of a venous segment or other replacement valve and an associated stent is color-coded to allow for easier determination of a particular configuration. For example, such a visual indicator can be used to identify which end of the valve is the inflow end and which end of the valve is the outflow end. In a particularly preferred embodiment, the suturing at the outflow end and/or inflow end of the valve is colored to match that portion of an associated delivery device intended to be adjacent the end of the valve when properly mounted to the device. Other methods of providing a colored marking may be provided in addition to or in substitution for sutures.


In another aspect of the invention, a prosthetic valve and delivery system is provided, with the valve being mountable to the delivery system in correct or incorrect manners. The prosthetic valve comprises a replacement valve having a substantially tubular valve body wall, an expandable stent having a framework with first and second ends, and sutures holding the framework to the valve body wall at the first and second ends. The sutures at the first end are colored differently from the suturing at the second end. The delivery system is provided with a colored component of generally the same color as the sutures at the first end of the framework and the colored component is located such that when the valve is correctly mounted to the delivery system, the colored component is adjacent to the first end of the framework. Alternatively, the system may be provided with a colored marker located at one of the first and second ends of the framework, rather than the colored sutures. When the valve is correctly mounted to the delivery system, the colored component is adjacent to the colored marker. In a further alternative, the replacement valve (rather than the stent framework) has first and second ends, wherein one of the ends includes a colored marker that is located relative to the delivery system such that when the valve is correctly mounted, the colored component is adjacent to the colored marker.





BRIEF DESERTION OF THE DRAWINGS

The present invention will be further explained with reference to the appended Figures, wherein like structure is referred to by like numerals throughout the several views, and wherein:



FIG. 1 is a top perspective view of an exemplary stent for use in conjunction with the present invention;



FIG. 2 is cross-sectional side view of an exemplary valved venous segment for use in conjunction with the present invention;



FIG. 3 is a perspective view of an exemplary method of marking the venous segment prior to beginning the process of suturing the venous segment to its associated stent;



FIG. 4 is a top view of an exemplary method for placing of sutures for marking the position of valve commissures of the venous segment, such as the venous segment of FIG. 3;



FIGS. 5-11 illustrate several exemplary sequential steps that can be performed in providing an assembly including a stent and a venous segment, where each of these Figures is summarized in further detail as follows:



FIG. 5 is a top view of an assembly showing an exemplary initial placement of a stent over the venous segment, with both elements positioned on a mandrel;



FIG. 6 is a top view of the assembly of the type illustrated in FIG. 5, and further illustrating an exemplary final positioning of the venous segment relative to the stent;



FIG. 7 is a top view of the assembly of the type illustrated in FIG. 6, and further illustrating a technique of suturing the ends of the stent to the venous segment;



FIG. 8 is a top view of an assembly of the type illustrated in FIG. 7, and further illustrating both of the stent ends secured to the vein segment;



FIG. 9 is a top view of an assembly of the type illustrated in FIG. 8 and further illustrating an exemplary technique for trimming the venous segment to the approximate length of the stent;



FIG. 10 is a top view of an assembly of the type illustrated in FIG. 9 and further showing the venous segment after being trimmed to match the stent;



FIG. 11 is a top view of an assembly of the type illustrated in FIG. 10 and further illustrating the final steps of suturing the stent to the venous segment;



FIG. 12 is a top view of an exemplary delivery system for an assembled stented venous segment; and



FIG. 13 is a top view illustrating an exemplary operation of the delivery system of FIG. 12.





DETAILED DESCRIPTION

Referring now to the Figures, wherein the components are labeled with like numerals throughout the several Figures, and initially to FIG. 1, one configuration of an exemplary stent 10 for use in conjunction with the present invention is illustrated. The stent 10 as illustrated corresponds generally to a stent of the type described in the above-cited Tower, et al., and Bonhoeffer et al. references, for example. The stent 10 may be fabricated of platinum, stainless steel or other biocompatible metal. Stent 10 may alternatively be fabricated using wire stock as described in the above-cited Tower, et al. applications, or the stent 10 may be produced by machining the stent from a metal tube, as is commonly employed in the manufacturing of stents. The number of wires, the positioning of such wires, and various other features of the stent can vary considerably from that shown in the figures. The stent can be used in conjunction with bovine jugular vein segments in which the stent would typically be in the range of about 16 mm to 20 mm in diameter when expanded. The specifics of the stent can vary widely within the scope of the invention, such that many other known generally cylindrical stent configurations may be used and are considered to be within the scope of the invention.


The stent 10, like most expandable cylindrical stents, generally takes the form of a series of zig-zag ring structures, such as are indicated by reference number 18. The structures 18 are coupled longitudinally to one another to form a generally cylindrical-shaped structure, although it is understood that the structures 18 can form be arranged in an at least slightly oval or elliptical shape. Each ring structure 18 takes the form of a series of adjacent generally straight sections (e.g., 12, 14) which each meet one another at one end at a curved or angled junction (e.g., junction 16) to form a “V” or “U” shaped structure. For purposes of the present application, this structure will be referred to as a “V”, and the included junction (e.g., junction 16) is referred to as the base of the “V”. The relatively straight portions (e.g., straight sections 12, 14) of the stent between the bases of the “V”s, are referred to herein as the “arms” of the “V” or simply as “arms”. While the angled junctions illustrated take the form of relatively sharply angled junctions, the “V” terminology is also intended to include more gradually curved junctions as well, such as might be shaped more like a “U” with arms that are angled away from each other at least slightly.


Stents of the type illustrated are generally sized to be in the 16 mm to 20 mm diameter range when expanded, and are configured so that the bases of the “V”s are preferably spaced no further than about 8 mm from one another around the circumference of the stent. It should also be understood that although the ring structures are coupled to one another at the base of each “V” in the illustrated embodiment, stents employed according to the present invention may employ ring structures coupled to one another at fewer bases of their “V”s or coupled to one another by additional and/or different structures, such as longitudinal members of the type disclosed in U.S. Pat. No. 6,773,455, issued to Allen, et al., U.S. Pat. No. 6,641,609, issued to Globerman and in U.S. Pat. No. 6,136,023, issued to Boyle. The invention also includes within its scope those stents in which wires are formed into zig-zags and wound spirally to produce a cylindrical structure, as in U.S. Pat. No. 6,656,219, issued to Wictor or woven stents as disclosed in U.S. Pat. No. 4,655,771, issued to Wallsten.


Stents of the type described above, such as stent 10, can be assembled into a pulmonary valve assembly in accordance with the methods of the invention described herein. The pulmonary valve assemblies can be utilized in for purcutaneous replacement of cardiac valves, for example. One exemplary method for assembling a stented valve generally first includes preparation of a vein segment, then a subsequent mounting or attachment of the prepared vein segment to the stent, which are described below in further detail.



FIG. 2 illustrates a cross-sectional view of a vein segment 20 of the type that is appropriate for use in construction of the valve assembly. The embodiment illustrated may exemplify a preserved bovine jugular vein of the type described in the above-cited Bonhoeffer, et al. and Tower, et al. references, but other vessels or donor species may alternatively be employed. Alternatively, other replacement valves with substantially tubular valve bodies may be substituted. The vein segment 20 as illustrated includes leaflets 22 extending from the wall of the vein segment 20 from leaflet bases 24 (i.e., bottoms of leaflets 22) to commissures 26, which define the outer meeting points of the furthest downstream portions of the leaflets 22. The vein segments used for the present invention are generally referred to herein as being tubular or substantially tubular in shape, which are typical shapes in which vein segments are provided, although the vein segments can be somewhat irregular or differently shaped, such as elliptical or the like. In any case, the description of the vein segments or valves herein as being tubular or generally tubular is meant to encompass any such shapes. The vein segment 20 further includes an inflow end 28 through which blood will enter the vein segment 20 and an outflow end 27 through which blood will exit the vein segment 20.


The vein segment 20 preferably has three leaflets 22, but may optionally have less. The leaflets 22 of the vein segment 20, in their closed position, should have the capability to hold fluid for at least five seconds, and there should preferably be no branches in that portion of the vein wall which will ultimately be located in the stent.


In a particular procedure, a vein segment 20 of an appropriate length is selected for attachment to a desired stent. The wall of the vein segment 20 is then measured to determine its wall thickness. As described in the above-cited Bonhoeffer, et al and Tower, et al. references, for example, if the vein segment 20 has a wall thickness greater than about 0.5 mm, the vein segment 20 will preferably be thinned to leave a wall thickness of no more than about 0.5 mm. This thinning process may be performed in a variety of ways, one of which includes placing the vein onto a mandrel, then trimming the adventitial tissue. One method of performing the thinning includes pulling the adventitia from the wall of the vein, then using a cutting instrument, such as scissors, to snip or cut the tissue fibers until as much of the tissue fibers are removed as necessary to achieve a desired wall thickness. After the thinning process is complete, the tissue may appear to be relatively translucent.


Either prior to or subsequent to the thinning operation described above, the vein segment 20 can be trimmed to a desired length for attachment to a stent in order to easier perform the steps of securing the vein segment 20 to a stent 10. This step would not be necessary if the vein segment 20 has been provided in the desired length, such as from some type of preparation location. In at least one exemplary process in which vein segment trimming is desired, the vein segment 20 is trimmed at a first location 30 spaced from inflow end 28 and/or at a second location 32 spaced from output end 27 to leave a minimum of about 15 mm of tissue from the tops of the commissures 26 and the bottoms 24 of the leaflets 22 to the ends of the vein segment 20. If the vein segment 20 is trimmed in this way, the inflow end 28 and outflow end 27 will then be shifted to these new locations where the vein segment 20 was trimmed. It is understood that the distance from the tops of the commissures 26 and the bottoms 24 of the leaflets 22 to the ends 27, 28 can be more or less than 15 mm, as desired or necessary for attachment to differently sized stents, where the 15 mm distance is desirable and common for at least some valve assemblies. In any case, it is desirable to provide a long enough vein segment 20 to accomplish the remaining steps of the assembly method that is not so long that it interferes with the attachment procedure.


Next, FIG. 3 illustrates one exemplary manner of locating and marking the top of each commissure 26 on the outside of the vein segment 20. First, a forceps 44 is positioned close to, but at a minimum of 1 mm above the top of each commissure 26 of vein segment 20. The forceps 44 are squeezed together to make an impression on the wall of the vein segment 20. This leaves a temporary mark 52 (see FIG. 4) on the outer wall of vein segment 20 to indicate where to place a suture. It is contemplated that other tools or methods may be used to provide a mark in a similar location on the outside of the vein segment 20.


Next, as is illustrated in FIG. 4, a needle 48 is carefully inserted into each marked area 52 of the vein segment 20. Needle 48 is preferably threaded with a colored suture material 50. In a desired method, the needle 48 should not extend through the entire thickness of the vein segment 20, but should only penetrate through a portion of the thickness of vein segment 20. After bringing the suture 50 through the marked area 52, the suture 50 is loosely secured, such by tying it into a very loose square knot 54 (see FIG. 5) or by using another securing technique that allows a temporary positioning of the suture 50. The process of marking the outside of the vein segment 20 and providing a temporary suture should be performed in the area of each of the commissures 26. The vein segment 20 is now prepared for mounting to the stent 10.


If an alternative replacement material for valves is employed instead of a bovine jugular vein segment, it will be prepared for mounting to the stent as appropriate for the particular valve chosen. For example, it may be prepared as described in the above-cited patents issued to Cox. Thus, the particular preparation techniques described above may not be necessary for all types of vein segments, although it is desirable that other types of vein segments are provided with some type of marking on its outer surface to indicate the location of the commissures.


One exemplary method of mounting the vein segment 20 or other replacement valve to the stent 10 is described below with particular reference to FIGS. 5-11. The suturing procedure described may be performed on a mandrel or while simply manually holding the vein segment 20 or other replacement valve. Use of a mandrel is particularly applicable if a bovine valved venous segment is employed, but may or may not also be appropriate for other replacement valves. In the below description of an exemplary process, however, a mandrel is described for use in the mounting procedure.


First, as illustrated in FIG. 5, the vein segment 20 is slid partially onto a mandrel 40 (e.g., for about ¼ of the length of the vein segment 20), so that the outflow end 27 extends beyond the end of the mandrel 40. The stent 10 is placed over or around the vein segment 20 so that an outflow portion 56 of the stent 10 overlies knots 54, which were made as described above in conjunction with FIG. 4. The mandrel 40 is then slid further through the vein segment 20 and stent 10. The vein segment 20 may stretch to accommodate the outer diameter of the mandrel 40, which may be at least slightly larger than the inner diameter of the vein segment 20. It may be necessary in some cases to temporarily stop the movement of the mandrel 40 through the vein segment 20 in order manually adjust the stent 10 to keep it properly positioned relative to the vein segment 20 and to accommodate any stretching. In any case, the mandrel 40 is then moved further relative to the vein segment 20 and stent 10 until the outflow end 27 of vein segment 20 no longer extends past the end of mandrel 40.



FIG. 6 shows the vein segment 20 and stent 10 as positioned completely on the mandrel 40. At this point, the stent 10 can be adjusted to achieve a desired position of the stent 10 relative to the vein segment 20 and its associated structure (e.g., the commissures 26). In order to adjust the position of stent 10, a tool such as a dull-tipped forceps 58, for example, can be used to gently move the tissue of the vein segment 20 so that the locations of the commissure tops (which were previously marked by knots 54), are in a desired position relative to the stent 10. In one exemplary embodiment, the knots 54 and corresponding tops of commissures 26 will be positioned at least 1 mm away from the base 16 of the nearest “V” and at least 1 mm away from the adjacent arms 12, 14 of the stent 10. This positioning of the vein segment 20 will help avoid stitching the arms 12, 14 and/or base portion 16 of the “V” portions into the leaflets 22. The tops of the commissures 26 and the leaflets 22 are then preferably positioned within the frame of the stent 10. In order to verify the positioning of the vein segment 20, a light source can optionally be used to view the components, such as can be accomplished by using the room light as back lighting. However, if the vein segment 20 is manipulated to the point that it twists the commissures 26 or distorts the leaflets 22, the vein segment may need to be further examined and adjusted or replaced.


After the vein segment 20 is positioned as desired relative to the stent 10, an area of the stent 10 nearest the outflow end 27 of vein segment 20 (which may be referred generally to as an outflow end 56 of the stent 10) will then be sutured or attached to the vein segment 20, as illustrated in FIG. 7. In this suturing process, the suture material used is preferably easily visible to the human eye, and visually distinct such as may be provided by a suture material having a color that is at least somewhat darker or lighter in color than the vein segment 20 and/or the stent 10. For example, the suture material may be provided as a blue, 5-0 suture material. The suture material may be provided as a monofilament or multifilament structure made of natural or synthetic materials (e.g., nylon or polypropylene), or may alternatively include an elongated metal or metal-composite thread or filament or any other material that is suitable for permanently securing the stent to a vein segment in accordance with the present invention. The suture material is threaded onto a needle for the suturing process.


To begin the suturing process, suture material is threaded into the vein segment 20 under one side of the base 16 of a “V” at a location 60. The suture is then pulled through to the opposite side of the base 16 of the “V”, preferably leaving an extending tail 62 of suture material, which may be approximately 2 cm in length, for example. The suture material is then made into a loop and the needle is threaded through the loop. The two ends of suture material are then pulled to make a locking knot 64 around the stent 10 at the base 16 of one of the “V”s. While it is important to pull the knot relatively tight, the knot should not be pulled so tight that it bends the wire of the stent 10. The suture is then looped around one arm 12 of the “V”, such as at a location 66, by inserting the needle through the vein segment 20 under the stent 10 and adjacent to the arm 12 and pulling the suture taut. This creates a first whipstitch around the arm 12. The described step of inserting the needle through the vein segment 20 under the stent 10 is preferably repeated at least 3 more times to create a total of at least 4 whipstitches around the arm 12. Although it is possible that more or less than 4 whipstitches can be used along a particular arm 12, the number of stitches used should be sufficient to provide secure attachment of each arm 12, 14 of the stent 10 to the vein segment 20. Each sequential placement of a whipstitch is positioned at a progressively further distance from the locking knot 64. At the same time, each of these whipstitches will be placed at a distance that is progressively closer to the base of an adjacent “V” at the opposite end of the arm 12, such as is illustrated as a location 68.


Once the next base of a “V” is reached at 68, another locking stitch should be made around the stent 10 by again making a loop with the suture, pulling the thread through the loop, and tightening the knot around the base 16 at location 68. The locking stitch at the base 16 of each “V” should also be secured to the vein segment 20 by passing the thread at least partially through the vein segment 20 during the process of making the locking stitch. These steps will then be repeated along each of the arms 12, 14 around the outflow end 56 of the stent 10 until the suture tail 62 is reached. That is, a series of preferably at least 4 whipstitches should be made along each of the arms 12, 14 around the circumference of stent 10, with a locking stitch at each base 16, although it is possible that less than 4 whipstitches can be used along one or more of the arms 12, 14. The whipstitches are preferably continuous and uninterrupted around the circumference of stent 10.


Once the suture tail 62 is reached, a final locking stitch is made. To do this, the suture tail 62 is preferably tied off with a double throw square knot by wrapping the longer suture tail twice around the tool used to hold the needle (e.g., a needle holder resembling pliers) and pulling the shorter suture tail through the loops. The tying off process is preferably finalized by making a single throw square knot by wrapping the longer suture tail once around the needle holder and pulling the shorter suture tail through the loop. The knots should both be tightened to provide a more secure attachment. The shorter suture tail is then trimmed at a location close to the stent 10, preferably without cutting into any of the stitches or tissue. The suture is then preferably threaded under the stent 10 to pull the knot behind the stent 10. The suture can be trimmed relatively close to the stent 10. At this point, the structure includes stitching extending completely around the outflow end 56 of the stent 10.


While the above description provides one sequence of suture loops and knots for securing the suture material, a different series of knots and suture manipulation may alternatively be utilized, so long as such process provides a secure attachment of the stent to the vein segment along the various segments of the stent described herein. In particular, the knots and stitches provided in the suture should not be capable of disengaging from the stent and/or vein segment and should not interfere with the leaflets of the vein segment.


The above steps are then repeated at the inflow end 57 of the stent 10 using a suture material that is visually distinct from the suture used at the outflow end 56 of stent 10. For one example, white or clear 5-0 suture material can be used to stitch the vein segment 20 to the inflow end 57 of the stent 10 to produce a stented valve. The suture material used at the inflow end 57 may be the same as or different from the suture material used at the outflow end 56, which may also be the same as or different from the suture material used at any additional locations where sutures are used to attach the stent to the vein segment. The structure is illustrated as a stented valve 70 in FIG. 8, which shows a stent 10 that is stitched to the vein segment 20 around the circumference of both its inflow end 57 and its outflow end 56. Although it is possible in another exemplary method of the invention to stitch the inflow end 57 to vein segment 20 before stitching the outflow end 56 to vein segment 20, another procedure and/or device would need to be used to insure that the outflow end 56 will remain properly positioned relative to the commissures 26 during the process of stitching the inflow end 57.


The use of different colored sutures at the inflow end 28 and outflow end 26 of the stent 10 can assist a physician in mounting the stented valve in its proper orientation to its delivery device, as discussed below. In the event that alternative replacement valves are employed, the locations of the colored sutures may differ from that described above, but they preferably should be located at or adjacent to the inflow and/or outflow ends of the valve. Similarly, if alternative stents are employed, the particular stitching pattern may vary to accommodate the specific configuration of the stent. In any of these configurations, however, a visual indicator at one end of the stent and/or vein segment is preferably used to be sure to achieve the correct orientation of the valve relative to the delivery device with which it will be used.


Following the procedure of stitching the stent 10 to the vein segment 20, the stented valve 70 is removed from the mandrel 40. The edges of the vein segment 20 that extend beyond the stent 10 are then trimmed to generally follow the contour of the edges of stent 10, as illustrated in FIG. 9. In an exemplary process, the vein segment 20 is cut approximately 1 mm away from the frame of the stent 10 without cutting into any of the sutures. FIG. 10 illustrates the stented valve 70 after completion of the procedure. For replacement valves other than bovine jugular valve segments, this trimming operation may not be required.


To provide for an even more secure attachment of the vein segment 20 to the stent 10 and to prevent or minimize inward bowing of the walls of the vein segment 20, suture material may be used to provide additional locations for attachment of the vein segment 20 to the stent 10. FIG. 11 illustrates such an exemplary attachment configuration, although all of the attachment locations shown may not be desirable or necessary for every stented valve. That is, either some or all of the additional attachment locations described below may be used for a stented valve.


With particular reference to FIG. 11, suture material is used to secure the vein segment 20 at each sinus area 72, which are each located generally between the commissures. Suture material can also be used to secure the vein segment 20 at substantially all or more preferably at the base of every “V” (e.g., at locations 74, 76, 78, etc.). The stented valve 70 is preferably not on a mandrel when making these stitches and the suture material used for these additional stitches is preferably clear, such as a 5-0 clear suture.


One exemplary method to secure the vein segment 20 in the sinus areas includes first locating the single “V” of the stent that is most centered in each sinus area 72. It is acceptable for the “V” chosen for stitching to point toward either outflow end 56 or inflow end 57 of stented valve 70. Starting at the base of this “V”, the suture is threaded under the stent 10 and a single throw securing square knot is made, followed by a double throw securing knot. The vein segment 20 is then stitched to the arms of that “V” with preferably at least 4 whipstitches per arm and a locking stitch at the base of the “V” as described above in conjunction with suturing the vein segment 20 to the ends 56, 57 of the stent 10. As with the previously described securing processes, more or less than 4 whipstitches may be used, depending on a number of factors, including the size of the stent and the length of the arms that make up its structure. In any case, the number of stitches used should be sufficient to provide secure attachment of the stent portions to the vein segment. The suture is then tied off or terminated, preferably with three locking stitches. The resulting knot can be tucked behind the stent and the suture tails trimmed as close to the knot as possible. After stitches are provided along the length of both arms, the stented valve 70 will include a “V” shaped area 79 where the stent 10 is secured to the vein segment 20, as shown in FIG. 11. This process is preferably repeated for each sinus area of the stented valve 70. In this process, if the replacement valve is other than a bovine vein segment, securement of the valve body or vein segment to the stent in the sinus areas as illustrated may not be necessary or desirable.


Next, the vein segment is secured at the bases of some or all of the remaining “V”s of the stent using the following exemplary process: First, a suture is passed through the vein segment behind the base of the “V”, taking care not to sew through the leaflets. A single throw knot is then made, followed with a two throw securing knot. The suture tails are then trimmed relatively close to the knot to minimize the length of extending suture material. This process is repeated for the base of each of the “V”s that is to be secured in this manner. When the desired “V” bases are sutured, there is preferably no portion of the vein wall or other tubular valve body wall more than 7 mm from a suture, and more preferably no more than 5 mm from a suture. The stented valve can then be sterilized and packaged.


By suturing the vein segment to the stent to all or substantially all of the bases of the “V”s, inward ballooning of the vein segment as described in the article: Remblacement Valvulaire Pulmonaire par voie Percutanee: Vers une Modifiction de la Prothese, Boudjemline, et al. Arch Mal Cour 2003:96:461-6 may be avoided or controlled. With the methods and valves described herein, the suturing pattern assures that no point on the vein wall is more than about 5 mm from a supporting suture, particularly when all of the bases of the “V”s are secured to the vein segment. In stents as illustrated or in stents with other geometries, the same result could be obtained by ensuring that regardless of the specific stent element sutured to the vein segment, there are no areas of the vein wall or other tubular valve body wall that are more than 7 mm from a suture, and preferably that there are no areas of the vein wall or other tubular valve body wall more than 5 mm from a suture.



FIG. 12 illustrates a system for delivering a stented valve (e.g., the stented valve 70 of FIG. 11) to a desired implant location, such as the pulmonary vein, a valved conduit or other location. The delivery system 80 comprises an outer sheath 82 overlying an inner balloon catheter (not visible in this Figure). The outer sheath has an expanded distal portion 84, within which the stented valved venous segment is located. The stented valve is compressed around a single or double balloon located on the inner balloon catheter. A tapered tip 86 extends from the distal end of the inner balloon catheter and serves to ease the passage of the delivery system through the vasculature. The tapered tip 86 may be color-coded to match the color of the suture on the stented valve that will be used. For example, if a blue suture material is used nearest the end of the stented valve 70 that is to be closest to the tapered tip 86, the tapered tip 86 may also be blue in color in order to provide an easy visual indicator of the proper orientation of the valve 70. The system may also include a guidewire 88, which may be, for example, a 0.089 cm extra stiff guidewire as manufactured by Amplatzer, Golden Valley, Minn. The guidewire can be used to guide the delivery system to its desired implant location.


While the above description refers primarily to the use of colored suture material as a visual indicator for the orientation of a stented valve, another type of visual indicator, indicia, symbol or marker can be used in addition to or instead of the colored suture materials. For example, the delivery system can be provided with some type of symbol, indicia, pattern, or marker that matches or otherwise corresponds with a symbol, pattern, or color on one end of the stented valve to guide the user in properly orienting the stented valve relative to the delivery system. It is further possible that opposite ends of the stented valve are made to be visually distinct from each other through the use of the same or different suture materials that are routed or stitched differently on each end to provide a different visual effect. The corresponding delivery system includes some type of indicator that corresponds to one or both of the suture patterns to provide a guide to the proper orientation of the valved stent. In another alternate configuration, the stented valve itself may have a geometrical configuration at one or both of its ends that matches a feature or features on the delivery system to facilitate both proper placement and orientation of the stented valve relative to the delivery system. These described combinations of colors, materials, patterns, and other markers that can be used in accordance with the invention are exemplary configurations, where other combinations are possible that include at least one visual indicator on a stented valve that is provided to correspond with a visual indicator on its corresponding delivery system.


The delivery system and its use may correspond to that described in the above-cited Tower, et al. applications. The delivery system is advanced to the desired valve implant site using the guidewire 88, after which the sheath 82 can be retracted to allow balloon expansion of the venous segment, as illustrated in FIG. 13, as discussed below.



FIG. 13 illustrates an exemplary mechanism for deployment of the stented valve 70. The outer sheath 82 is moved proximally, exposing a balloon 92 mounted on an inner catheter 90. The balloon 92 can then be expanded, thereby expanding stented valve 70 against the inner surface of the previously implanted adapter stent, stabilizing and sealing the venous segment within the adapter stent. The balloon can then be deflated and the delivery system withdrawn proximally.


In the case of a stented valve made using bovine jugular vein or other preserved biological tissue, the stented valve can be sterilized, stored and shipped separately in a buffered glutaraldehyde solution, but typically not pre-mounted on the delivery system. However, it is possible that the stented valve can also be pre-mounted on the delivery system if the system with a valve mounted thereon is similarly sterilized and kept in a sterile environment. In many cases, however, the implanting physician or an assistant will perform the step of mounting the stented valve 70 to the balloon 92. Because it is not always easy to visually determine which end of the valve is the outflow end, there is a possibility that the valve might be placed incorrectly on the balloon, which would result in an unacceptable implantation procedure. In the embodiment illustrated, however, the suturing 100 at the outflow end 56 of the stent 10 is easy to identify because it is blue in color to preferably correspond to a blue color of the adjacent tip 86. So long as the person mounting the valve to the balloon remembers to match the color of the suture material at the outflow end 56 of the stent 10 to the color of the tip 86, the possibility of a mistake is minimal.


In addition, as described in the above-cited Tower, et al. patent applications, the inner catheter 90 may be provided with a collar 94, which is intended to engage the proximal end of expanded distal portion 84 of the outer sheath 82. The collar may be white, corresponding to the sutures 102 that are white or clear, for example, and located at the inflow end 57 of the stent 10 adjacent the collar, further assisting in proper location of the stented valve 70. While the colored markings on the stented valve are provided by means of colored sutures in the preferred embodiment described above, other methods of marking, such as colored inks or dyes or other colored components might be used in substitution for or in addition to colored suture material.


The present invention has now been described with reference to several embodiments thereof. All patents, patent applications, publications and journal articles mentioned herein are incorporated herein by reference in their entirety. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. It will be apparent to those skilled in the art that many changes can be made in the embodiments described without departing from the scope of the invention. Thus, the scope of the present invention should not be limited to the structures described herein, but only by the structures described by the language of the claims and the equivalents of those structures.

Claims
  • 1. A prosthetic valve and delivery system, the valve mountable to the delivery system in either first or second orientations, wherein the prosthetic valve comprises: a valve member;an expandable stent having a first portion and a second portion; anda plurality of sutures holding the valve member to the stent at the first and second portions, wherein the sutures at the first portion are colored differently than the sutures at the second portion;wherein the delivery system includes at least one colored visual indicator that corresponds with the sutures at the first portion of the stent, wherein the colored visual indicator is generally the same color as the sutures at the first portion of the stent; andwherein the at least one colored visual indicator is located such that when the prosthetic valve is mounted in the first orientation relative to the delivery system, the at least one colored visual indicator is adjacent to the first portion of the stent.
  • 2. The prosthetic valve and delivery system of claim 1, wherein the first orientation of the prosthetic valve relative to the delivery system corresponds to a correct valve orientation, and wherein the second orientation of the prosthetic valve relative to the delivery system corresponds to an incorrect valve orientation.
  • 3. The prosthetic valve and delivery system of claim 1, the expandable stent further comprising an intermediate portion between the first and second portions wherein the plurality of sutures include an intermediate suture located at the intermediate portion to attach the valve member to the stent at the intermediate portion.
  • 4. The prosthetic valve and delivery system of claim 1, wherein the colored visual indicator is a symbol.
  • 5. The prosthetic valve and delivery system of claim 1, wherein the colored visual indicator is a pattern.
  • 6. The prosthetic valve and delivery system of claim 1, wherein the first portion of the stent comprises an inflow end of the prosthetic valve.
  • 7. The prosthetic valve and delivery system of claim 1, wherein the first portion of the stent comprises an outflow end of the prosthetic valve.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional application having Ser. No. 60/629,468 filed Nov. 19, 2004, entitled “APPARATUS FOR TREATMENT OF CARDIAC VALVES AND METHOD OF ITS MANUFACTURE,” which application is incorporated herein by reference in its entirety. This application is a divisional application of U.S. Pat. No. 8,562,672, filed Nov. 18, 2005, the disclosure of which is incorporated herein by reference in its entirety.

US Referenced Citations (479)
Number Name Date Kind
3334629 Cohn Aug 1967 A
3409013 Berry Nov 1968 A
3540431 Mobin-Uddin Nov 1970 A
3587115 Shiley Jun 1971 A
3628535 Ostrowsky et al. Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3795246 Sturgeon Mar 1974 A
3839741 Haller Oct 1974 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4233690 Akins Nov 1980 A
4291420 Reul Sep 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4425908 Simon Jan 1984 A
4470157 Love Sep 1984 A
4501030 Lane Feb 1985 A
4574803 Storz Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4610688 Silvestrini et al. Sep 1986 A
4612011 Kautzky Sep 1986 A
4647283 Carpentier et al. Mar 1987 A
4648881 Carpentier et al. Mar 1987 A
4655771 Wallsten Apr 1987 A
4662885 DiPisa, Jr. May 1987 A
4665906 Jervis May 1987 A
4681908 Broderick et al. Jul 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz Mar 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4834755 Silvestrini et al. May 1989 A
4856516 Hillstead Aug 1989 A
4872874 Taheri Oct 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4922905 Stecker May 1990 A
4954126 Wallsten Sep 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5002559 Tower Mar 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5061273 Yock Oct 1991 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5217483 Tower Jun 1993 A
5232445 Bonzel Aug 1993 A
5272909 Nguyen et al. Dec 1993 A
5295958 Shturman Mar 1994 A
5327774 Nguyen et al. Jul 1994 A
5332402 Teitelbaum et al. Jul 1994 A
5350398 Pavcnik et al. Sep 1994 A
5370685 Stevens Dec 1994 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5411552 Andersen et al. May 1995 A
5415633 Lazarus et al. May 1995 A
5431676 Dubrul et al. Jul 1995 A
5443446 Shturman Aug 1995 A
5480424 Cox Jan 1996 A
5489294 McVenes et al. Feb 1996 A
5496346 Horzewski et al. Mar 1996 A
5500014 Quijano et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5545209 Roberts et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5575818 Pinchuk Nov 1996 A
5580922 Park et al. Dec 1996 A
5591195 Taheri et al. Jan 1997 A
5609626 Quijano et al. Mar 1997 A
5645559 Hachtman et al. Jul 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5695498 Tower Dec 1997 A
5702368 Stevens et al. Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5749890 Shaknovich May 1998 A
5766151 Valley et al. Jun 1998 A
5782809 Umeno et al. Jul 1998 A
5800456 Maeda et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824061 Quijano et al. Oct 1998 A
5824064 Taheri Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5860966 Tower Jan 1999 A
5861028 Angell Jan 1999 A
5868783 Tower Feb 1999 A
5876448 Thompson et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5913842 Boyd et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5944738 Amplatz et al. Aug 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5997573 Quijano et al. Dec 1999 A
6022370 Tower Feb 2000 A
6027525 Suh et al. Feb 2000 A
6029671 Stevens et al. Feb 2000 A
6042589 Marianne Mar 2000 A
6042598 Tsugita et al. Mar 2000 A
6051014 Jang Apr 2000 A
6059809 Amor et al. May 2000 A
6110201 Quijano et al. Aug 2000 A
6123723 Konya et al. Sep 2000 A
6146366 Schachar Nov 2000 A
6159239 Greenhalgh Dec 2000 A
6162208 Hipps Dec 2000 A
6162245 Jayaraman Dec 2000 A
6164339 Greenhalgh Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6192944 Greenhalgh Feb 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6218662 Tchakarov et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6277555 Duran et al. Aug 2001 B1
6299637 Shaolia et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6309382 Garrison et al. Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6327772 Zadno-Azizi et al. Dec 2001 B1
6338735 Stevens Jan 2002 B1
6348063 Yassour et al. Feb 2002 B1
6352708 Duran et al. Mar 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6475239 Campbell et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508833 Pavcnik et al. Jan 2003 B2
6527800 McGuckin, Jr. et al. Mar 2003 B1
6530949 Konya et al. Mar 2003 B2
6559603 Iwami May 2003 B2
6562058 Seguin et al. May 2003 B2
6569196 Vesely May 2003 B1
6582462 Andersen et al. Jun 2003 B1
6585758 Chouinard et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6605112 Moll et al. Aug 2003 B1
6622604 Chouinard et al. Sep 2003 B1
6627873 Tchakarov et al. Sep 2003 B2
6632243 Zadno-Azizi et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6652571 White et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6656213 Solem Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673109 Cox Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6692513 Streeter et al. Feb 2004 B2
6695878 McGuckin, Jr. et al. Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6719789 Cox Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6736846 Cox May 2004 B2
6752828 Thornton Jun 2004 B2
6758855 Fulton, III et al. Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6786925 Schoon Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6792979 Konya et al. Sep 2004 B2
6797002 Spence Sep 2004 B2
6821297 Snyders Nov 2004 B2
6830575 Stenzel et al. Dec 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof Dec 2004 B1
6846325 Liddicoat Jan 2005 B2
6866650 Stevens Mar 2005 B2
6872223 Roberts Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6883522 Spence et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890330 Streeter et al. May 2005 B2
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6908481 Cribier Jun 2005 B2
6913600 Valley et al. Jul 2005 B2
6929653 Streeter Aug 2005 B2
6936066 Palmaz et al. Aug 2005 B2
6939365 Fogarty et al. Sep 2005 B1
6951571 Srivastava Oct 2005 B1
6986742 Hart et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6991649 Sievers Jan 2006 B2
7011681 Vesely Mar 2006 B2
7041128 Mcguckin, Jr. et al. May 2006 B2
7044966 Svanjdze et al. May 2006 B2
7048014 Hyodoh et al. May 2006 B2
7097659 Woolfson et al. Aug 2006 B2
7115141 Menz et al. Oct 2006 B2
7147663 Berg et al. Dec 2006 B1
7153324 Case et al. Dec 2006 B2
7160319 Chouinard et al. Jan 2007 B2
7175656 Khairkhahan Feb 2007 B2
7186265 Sharkawy et al. Mar 2007 B2
7195641 Palmaz et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201761 Woolfson et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7252682 Seguin Aug 2007 B2
7300457 Palmaz Nov 2007 B2
7300463 Liddicoat Nov 2007 B2
7316706 Bloom et al. Jan 2008 B2
7329278 Seguin Feb 2008 B2
7335218 Wilson et al. Feb 2008 B2
7338520 Bailey et al. Mar 2008 B2
7384411 Condado Jun 2008 B1
7399314 Butaric et al. Jul 2008 B2
20010002445 Vesely May 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010025196 Chinn et al. Sep 2001 A1
20010032013 Marton Oct 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010044591 Stevens et al. Nov 2001 A1
20020029014 Jayaraman Mar 2002 A1
20020032480 Spence et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020052651 Myers et al. May 2002 A1
20020058995 Stevens May 2002 A1
20020072789 Hackett et al. Jun 2002 A1
20020077696 Zadno-Azizi et al. Jun 2002 A1
20020095209 Zadno-Azizi et al. Jul 2002 A1
20020111674 Chouinard et al. Aug 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030028247 Cali Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030065386 Weadock Apr 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030109924 Cribier Jun 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149477 Gabbay Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199963 Tower et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030199972 Zadno-Azizi et al. Oct 2003 A1
20030212410 Stenzel et al. Nov 2003 A1
20030212452 Zadno-Azizi et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040088045 Cox May 2004 A1
20040093005 Durcan May 2004 A1
20040093060 Sequin et al. May 2004 A1
20040093075 Kuehne May 2004 A1
20040097788 Mourles et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040122516 Fogarty Jun 2004 A1
20040127979 Wilson Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040153146 Laskinski et al. Aug 2004 A1
20040167573 Williamson Aug 2004 A1
20040167620 Ortiz Aug 2004 A1
20040186563 Lobbi Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040210240 Saint Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215333 Duran Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040225353 McGuckin, Jr. Nov 2004 A1
20040225354 Allen Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260317 Bloom et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050033398 Seguin Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050049692 Numamoto Mar 2005 A1
20050049696 Siess Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050060029 Le Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075712 Biancucci Apr 2005 A1
20050075717 Nguyen Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075724 Svanidze Apr 2005 A1
20050075727 Wheatley Apr 2005 A1
20050075730 Myers Apr 2005 A1
20050075731 Artof Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050096692 Linder et al. May 2005 A1
20050096724 Stenzel et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050107871 Realyvasquez et al. May 2005 A1
20050113910 Paniagua May 2005 A1
20050119688 Bergheim Jun 2005 A1
20050131438 Cohn Jun 2005 A1
20050137686 Salahieh Jun 2005 A1
20050137692 Haug Jun 2005 A1
20050137695 Salahieh Jun 2005 A1
20050137701 Salahieh Jun 2005 A1
20050143809 Salahieh Jun 2005 A1
20050148997 Valley et al. Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203618 Sharkawy Sep 2005 A1
20050222674 Paine Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050234546 Nugent Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240263 Fogarty et al. Oct 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050283962 Boudjemline Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060009841 McGuckin et al. Jan 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058775 Stevens et al. Mar 2006 A1
20060089711 Dolan Apr 2006 A1
20060100685 Seguin et al. May 2006 A1
20060116757 Lashinski et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060167474 Bloom et al. Jul 2006 A1
20060195134 Crittenden Aug 2006 A1
20060206192 Tower et al. Sep 2006 A1
20060206202 Bonhoefer et al. Sep 2006 A1
20060247763 Slater Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060271081 Realyvasquez Nov 2006 A1
20060282161 Huynh et al. Dec 2006 A1
20070005129 Damm et al. Jan 2007 A1
20070005131 Taylor Jan 2007 A1
20070010878 Raffiee et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070027518 Case et al. Feb 2007 A1
20070027533 Douk Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070051377 Douk et al. Mar 2007 A1
20070073392 Heyninck-Janitz Mar 2007 A1
20070078509 Lotfy et al. Apr 2007 A1
20070078510 Ryan Apr 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070093869 Bloom et al. Apr 2007 A1
20070100439 Cangialosi May 2007 A1
20070112415 Barlett May 2007 A1
20070162102 Ryan et al. Jul 2007 A1
20070162113 Sharkawy et al. Jul 2007 A1
20070203391 Bloom et al. Aug 2007 A1
20070225681 House Sep 2007 A1
20070232898 Huynh et al. Oct 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070233237 Krivoruchko Oct 2007 A1
20070233238 Huynh et al. Oct 2007 A1
20070238979 Huynh et al. Oct 2007 A1
20070239265 Birdsall Oct 2007 A1
20070239266 Birdsall Oct 2007 A1
20070239269 Dolan et al. Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244544 Birdsall et al. Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244546 Francis Oct 2007 A1
20070244553 Rafiee et al. Oct 2007 A1
20070244554 Rafiee et al. Oct 2007 A1
20070244555 Rafiee et al. Oct 2007 A1
20070244556 Rafiee et al. Oct 2007 A1
20070244557 Rafiee et al. Oct 2007 A1
20070250160 Rafiee Oct 2007 A1
20070255394 Ryan Nov 2007 A1
20070255396 Douk et al. Nov 2007 A1
20070288000 Bonan Dec 2007 A1
20080004688 Spenser et al. Jan 2008 A1
20080009940 Cribier Jan 2008 A1
20080015671 Bonhoeffer Jan 2008 A1
20080021552 Gabbay Jan 2008 A1
20080133003 Seguin et al. Jun 2008 A1
20080147105 Wilson et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080213113 Lawrence et al. Sep 2008 A1
20080215144 Ryan et al. Sep 2008 A1
Foreign Referenced Citations (85)
Number Date Country
36 40 745 Jun 1987 DE
195 32 846 Mar 1997 DE
195 46 692 Jun 1997 DE
198 57 887 Jul 2000 DE
199 07 646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
0144167 Jun 1985 EP
0597967 Dec 1994 EP
0850607 Jul 1998 EP
1057459 Jun 2000 EP
1 057 460 Dec 2000 EP
1088529 Apr 2001 EP
0937439 Sep 2003 EP
1340473 Sep 2003 EP
1356793 Oct 2003 EP
0819013 Jun 2004 EP
1472996 Nov 2004 EP
2788217 Dec 1999 FR
2056023 Mar 1981 GB
1271508 Nov 1986 SU
9117720 Nov 1991 WO
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9315693 Aug 1993 WO
9504556 Feb 1995 WO
9529640 Nov 1995 WO
9614032 May 1996 WO
9814137 Apr 1998 WO
9829057 Jul 1998 WO
9836790 Aug 1998 WO
9912483 Mar 1999 WO
9933414 Jul 1999 WO
9940964 Aug 1999 WO
9947075 Sep 1999 WO
0009059 Feb 2000 WO
0041652 Jul 2000 WO
0044308 Aug 2000 WO
0044313 Aug 2000 WO
0047136 Aug 2000 WO
0047139 Aug 2000 WO
0067661 Nov 2000 WO
0105331 Jan 2001 WO
0135870 May 2001 WO
0149213 Jul 2001 WO
0154625 Aug 2001 WO
0162189 Aug 2001 WO
0164137 Sep 2001 WO
0197715 Dec 2001 WO
0236048 May 2002 WO
0241789 May 2002 WO
0243620 Jun 2002 WO
0247575 Jun 2002 WO
02060352 Aug 2002 WO
02036048 Oct 2002 WO
02100297 Dec 2002 WO
03003943 Jan 2003 WO
03003949 Jan 2003 WO
03011195 Feb 2003 WO
03028592 Apr 2003 WO
03030776 Apr 2003 WO
03037227 May 2003 WO
03015851 Nov 2003 WO
03094793 Nov 2003 WO
2004019811 Mar 2004 WO
2004019825 Mar 2004 WO
2004023980 Mar 2004 WO
2004041126 May 2004 WO
2004047681 Jun 2004 WO
2004058106 Jul 2004 WO
2004089250 Oct 2004 WO
2004089253 Oct 2004 WO
2004093728 Nov 2004 WO
2004105651 Dec 2004 WO
2005002466 Jan 2005 WO
2005004753 Jan 2005 WO
2005009285 Feb 2005 WO
2005011534 Feb 2005 WO
2005011535 Feb 2005 WO
2005023155 Mar 2005 WO
2005027790 Mar 2005 WO
2005046528 May 2005 WO
2008100599 Aug 2008 WO
Non-Patent Literature Citations (45)
Entry
Andersen, H.R. et al, “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J. (1992) 13:704-708.
Babaliaros, et al., “State of the Art Percutaneous Intervention for the Treatment of Valvular Heart Disease: A Review of the Current Technologies and Ongoing Research in the Field of Percutaneous Heart Valve Replacement and Repair,” Cardiology 2007; 107:87-96.
Bailey, “Percutaneous Expandable Prosthetic Valves,” In: Topol EJ, ed. Textbook of Interventional Cardiology. vol. II. Second edition. WB Saunders, Philadelphia, 1994:1268-1276.
Block, et al., “Percutaneous Approaches to Valvular Heart Disease,” Current Cardiology Reports, vol. 7 (2005) pp. 108-113.
Bonhoeffer, et al, “Percutaneous Mitral Valve Dilatation with the Multi-Track System,” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Oct. 1999, pp. 178-183.
Bonhoeffer, et al, “Percutaneous Replacement of Pulmonary Valve in a Right-Ventricle to Pulmonary-Artery Prosthetic Conduit with Valve Dysfunction,” Lancet (England), Oct. 21, 2000, pp. 1403-1405.
Bonhoeffer, et al, “Technique and Results of Percutaneous Mitral Valvuloplasty With the Multi-Track System,” Journal of Interventional Cardiology (United States), 200, pp. 263-268.
Bonhoeffer, et al, “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study,” Circulation (United States), Aug. 15, 2000, pp. 813-816.
Boudjemline, et al, “Images in Cardiovascular Medicine. Percutaneous Aortic Valve Replacement in Animals,” Circulation (United States), Mar. 16, 2004, 109, p. e161.
Boudjemline, et al, “Is Percutaneous Implantation of a Bovine Venous Valve in the Inferior Vena Cava a Reliable Technique to Treat Chronic Venous Insufficiency Syndrome?” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Mar. 2004, pp. BR61-BR66.
Boudjemline, et al, “Off-pump Replacement of the Pulmonary Valve in Large Right Ventricular Outflow Tracts: A Hybrid Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Apr. 2005, pp. 831-837.
Boudjemline, et al, “Percutaneous Aortic Valve Replacement: Will We Get There?” Heart (British Cardiac Society) (England), Dec. 2001, pp. 705-706.
Boudjemline, et al, “Percutaneous Closure of a Paravalvular Mitral Regurgitation with Amplatzer and Coil Prostheses,” Archives des Maladies du Coeur Et Des Vaisseaux (France), May 2002, pp. 483-486.
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study,” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Apr. 2002, pp. BR113-BR116.
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in Aortic Position: Preliminary Results in a Sheep Study,” European Heart Journal 22, Sep. 2001, p. 630.
Boudjemline, et al, “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs,” European Heart Journal (England), Jul. 2002, pp. 1045-1049.
Boudjemline, et al, “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study,” Journal of the American College of Cardiology (United States), Mar. 17, 2004, pp. 1082-1087.
Boudjemline, et al, “Percutaneous Valve Insertion: A New Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Mar. 2003, pp. 741-742.
Boudjemline, et al, “Stent Implantation Combined with a Valve Replacement to Treat Degenerated Right Ventricle to Pulmonary Artery Prosthetic Conduits,” European Heart Journal 22, Sep. 2001, p. 355.
Boudjemline, et al, “Steps Toward Percutaneous Aortic Valve Replacement,” Circulation (United States), Feb. 12, 2002, pp. 775-778.
Boudjemline, et al, “The Percutaneous Implantable Heart Valve,” Progress in Pediatric Cardiology (Ireland), 2001, pp. 89-93.
Boudjemline, et al, “Transcatheter Reconstruction of the Right Heart,” Cardiology in the Young (England), Jun. 2003, pp. 308-311.
Coats, et al, “The Potential Impact of Percutaneous Pulmonary Valve Stent Implantation on Right Ventricular Outflow Tract Re-Intervention,” European Journal of Cardio-Thoracic Surgery (England), Apr. 2005, pp. 536-543.
Cribier, A. et al, “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description,” Circulation (2002) 3006-3008.
Davidson et al., “Percutaneous therapies for valvular heart disease,” Cardiovascular Pathology 15 (2006) 123-129.
Henzel, et al., “Complications of percutaneous aortic valve replacement: experience with the Criber-Edwards™ percutaneous heart valve,” EuroIntervention Supplements (2006), 1 (Supplement A) A3-A8.
Huber, et al., “Do Valved Stents Compromise Coronary Flow?” Eur. J. Cardiothorac. Surg. 2004;25:754-759.
Khambadkone, “Nonsurgical Pulmonary Valve Replacement: Why, When, and How?” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Jul. 2004, pp. 401-408.
Khambadkone, et al, “Percutaneous Implantation of Pulmonary Valves,” Expert Review of Cardiovascular Therapy (England), Nov. 2003, pp. 541-548.
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Early and Medium Term Results,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-375.
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Impact of Morphology on Case Selection,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-642-IV-643.
Lutter, et al, “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation,” The Journal of Thoracic and Cardiovascular Surgery, Apr. 2002, pp. 768-776.
Lutter, et al, “Percutaneous Valve Replacement: Current State and Future Prospects,”Annals of Thoracic Surgery (Netherlands), Dec. 2004, pp. 2199-2206.
Medtech Insight, “New Frontiers in Heart Valve Disease,” vol. 7, No. 8 (2005).
Palacios, “Percutaneous Valve Replacement and Repair, Fiction or Reality?” Journal of American College of Cardiology, vol. 44, No. 8 (2004) pp. 1662-1663.
Ruiz, “Transcathether Aortic Valve Implantation and Mitral Valve Repair: State of the Art,” Pediatric Cardiology, vol. 26, No. 3 (2005).
Saliba, et al, “Treatment of Obstructions of Prosthetic Conduits by Percutaneous Implantation of Stents,” Archives des Maldies du Coeur et des Vaisseaux (France), 1999, pp. 591-596.
Webb, et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” Circulation (2006), 113;842-850.
Yonga, et al, “Effect of Percutaneous Balloon Mitral Valvotomy on Pulmonary Venous Flow in Severe Mitral Stenosis,” East African Medical Journal (Kenya), Jan. 1999, pp. 28-30.
Yonga, et al, “Percutaneous Transluminal Balloon Valvuloplasty for Pulmonary Valve Stenosis: Report on Six Cases,” East African Medical Journal (Kenya), Apr. 1994, pp. 232-235.
Yonga, et al, “Percutaneous Transvenous Mitral Commissurotomy in Juvenile Mitral Stenosis,” East African Medical Journal (Kenya), Apr. 2003, pp. 172-174.
Yonga, et al, “Percutaneous Balloon Mitral Valvotomy: Initial Experience in Nairobi Using a New Multi-Track Catheter System,” East African Medical Journal (Kenya), Feb. 1999, pp. 71-74.
Bonhoeffer, et al., “Percutaneous Insertion of the Pulmonary Valve,” Journal of the Amer. College of Cardiology, 2002; 39:1664-1669.
Bonhoeffer, et al., “Transcatheter Replacement of a Bovine Valve in Pulmonary Position,” Circulation, 2000; 102:813-816.
Khambadkone, et al., “Percutaneous Pulmonary Valve Implantation in Humans,” Circulation, 2005, 112(8):1189-1197.
Related Publications (1)
Number Date Country
20140058501 A1 Feb 2014 US
Provisional Applications (1)
Number Date Country
60629468 Nov 2004 US
Divisions (1)
Number Date Country
Parent 11282275 Nov 2005 US
Child 14059028 US